EcoDrugPlus

Growth Hormone Secretagogue Receptor B

Ensembl ID : ENSIPUG00000017489
Gene Symbol: GHSRB
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSIPUG00000018015
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSIPUG00000002197
Gene Symbol: GUCY1A2
1 Cross references
203 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSIPUG00000018070
Gene Symbol: GUCY1B1
3 Cross references
210 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 1

Ensembl ID : ENSIPUG00000022194
Gene Symbol: HSP90AA1.1
4 Cross references
330 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSIPUG00000022238
Gene Symbol: HSP90AA1.2
3 Cross references
345 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSIPUG00000021071
Gene Symbol: HSP90AB1
2 Cross references
339 Possible Orthologues:

High Mobility Group Box 1a

Ensembl ID : ENSIPUG00000018990
Gene Symbol: HMGB1A
4 Cross references
511 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSIPUG00000012743
Gene Symbol: HMGB1B
3 Cross references
509 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSIPUG00000011966
Gene Symbol: HRH1
3 Cross references
186 Possible Orthologues:

Histamine Receptor H2

Ensembl ID : ENSIPUG00000019788
Gene Symbol: HRH2
1 Cross references
182 Possible Orthologues:

Histamine Receptor H2a

Ensembl ID : ENSIPUG00000008054
Gene Symbol: HRH2A
4 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).